Eli Lilly (LLY)

The healthcare stock may not be running out of growth catalysts anytime soon.

You can sleep peacefully at night owning these Vanguard ETFs.

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Eli Lilly's deal involves an upfront payment of $115 million to Insilico, with additional payments tied to milestones.

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Eli Lilly is much more than just a weight loss stock.

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing stellar long-term clinical data for its atopic dermatitis (eczema) treatment, Ebglyss. The disconnect between the laboratory and the trading

It's not much of a contest right now.

The American corporate engine has proven far more durable than even the most optimistic analysts predicted just a year ago. As of March 27, 2026, final results for the fourth quarter of 2025 have confirmed a blended earnings growth rate of 14.2% for the S&P 500. This milestone

This critical cog of the artificial intelligence (AI) supply chain was notably reduced by Wall Street's savviest money managers and passive funds during the fourth quarter.

Tom Lee, a veteran Wall Street strategist, says the S&P 500 could hit 15,000 by 2030.

Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which evaluates WVE-007—an investigational RNA interference (RNAi) therapy targeting the INHBE gene—aims to revolutionize obesity treatment by focusing

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an...

The United States is currently witnessing a structural pivot of historic proportions, as the long-heralded "U.S. Industrial Renaissance" moves from a policy ambition to a tangible, factory-floor reality. Driven by over $3 trillion in reshoring and foreign direct investment (FDI) since late 2024, the center of gravity in the

As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early 2020s. M&A activity has surged to levels not seen since the historic peaks of 2021, with

This ETF has struggled so far this year.

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash deal valued at approximately $6.7 billion. The move, priced at $53.00 per share, marks the culmination of one of the most dramatic corporate turnarounds [...]

Even if you're starting with $0 today, you can still build up a million-dollar portfolio with regular monthly investments.

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses.

As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total deal values surged to a record-breaking $813.3 billion in Q1, a staggering leap that signals a

The company recently obtained approval for a higher-dose version of Wegovy.